You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 65 No. 10, October 2008 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (36)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Dementias
 •Neurogenetics
 •Lewy Body Disease
 •Movement Disorders
 •Parkinson Disease/ Parkinsonian Disorders
 •Nutritional and Metabolic Disorders
 •Nutrition/ Malnutrition
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations

Ozlem Goker-Alpan, MD; Grisel Lopez, MD; Joseph Vithayathil, BS; Joie Davis, APRN; Mark Hallett, MD; Ellen Sidransky, MD

Arch Neurol. 2008;65(10):1353-1357.

Background  Mutations in the glucocerebrosidase gene (GBA) result in Gaucher disease and can be associated with a phenotype characterized by adult-onset progressive neurologic deterioration and parkinsonism.

Objective  To define the clinical and neurologic spectrum of parkinsonian manifestations associated with GBA mutations.

Design, Setting, and Patients  A prospective case series of 10 patients (7 men and 3 women) with parkinsonism and GBA mutations evaluated at the National Institutes of Health Clinical Center.

Main Outcome Measures  The GBA genotypes were identified by means of DNA sequencing. Tests evaluating neurologic, motor, cognitive, ocular, and olfactory functions were performed and the results were analyzed by a single team.

Results  Genotyping identified GBA mutations N370S, L444P, and c.84dupG and recombinant alleles. The mean age at onset of parkinsonian manifestations was 49 years (range, 39-65 years), disease duration was 7.8 years (range, 1.2-16.0 years), and Unified Parkinson Disease Rating Scale part III score was 26.3 (range, 13-38). Half of the patients reported cognitive changes later in the disease course. Six patients were diagnosed as having Parkinson disease, 3 as having Lewy body dementia, and 1 as having a "Parkinson plus" syndrome. The most frequent nonmotor finding was olfactory dysfunction. Atypical manifestations included myoclonus, electroencephalographic abnormalities, and seizures.

Conclusions  In the homozygous and heterozygous states, GBA mutations are associated with a spectrum of parkinsonian phenotypes ranging from Parkinson disease, mostly of the akinetic type, to a less common phenotype characteristic of Lewy body dementia.


Author Affiliations: Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute (Drs Goker-Alpan and Sidransky, Mr Vithayathil, and Ms Davis), and Medical Neurology Branch, National Institute of Neurological Disorders and Stroke (Drs Lopez and Hallett), National Institutes of Health, Bethesda, Maryland.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(10):1278-1280.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Olfactory dysfunction in LRRK2 G2019S mutation carriers
Saunders-Pullman et al.
Neurology 2011;77:319-324.
ABSTRACT | FULL TEXT  

CNS expression of glucocerebrosidase corrects {alpha}-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy
Sardi et al.
Proc. Natl. Acad. Sci. USA 2011;108:12101-12106.
ABSTRACT | FULL TEXT  

GBA-associated PD presents with nonmotor characteristics
Brockmann et al.
Neurology 2011;77:276-280.
ABSTRACT | FULL TEXT  

Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease
Farfel-Becker et al.
Hum Mol Genet 2011;20:1375-1386.
ABSTRACT | FULL TEXT  

Olfaction in Parkin-associated Parkinson disease: Another enigma
Markopoulou and Chase
Neurology 2011;76:312-313.
FULL TEXT  

Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease
Ron et al.
Hum Mol Genet 2010;19:3771-3781.
ABSTRACT | FULL TEXT  

Multi-system disorders of glycosphingolipid and ganglioside metabolism
Xu et al.
J. Lipid Res. 2010;51:1643-1675.
ABSTRACT | FULL TEXT  

Nonmotor Symptoms in Genetic Parkinson Disease
Kasten et al.
Arch Neurol 2010;67:670-676.
ABSTRACT | FULL TEXT  

Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Maegawa et al.
J. Biol. Chem. 2009;284:23502-23516.
ABSTRACT | FULL TEXT  

The Expanding Role of Genetics in the Lewy Body Diseases: The Glucocerebrosidase Gene
Leverenz et al.
Arch Neurol 2009;66:555-556.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.